1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
Article first published online: 3 APR 2003
DOI: 10.1002/art.10876
Copyright © 2003 by the American College of Rheumatology
1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Additional Information
How to Cite
De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M. and De Keyser, F. (2003), Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis & Rheumatism, 48: 1015–1023. doi: 10.1002/art.10876
Publication History
- Issue published online: 3 APR 2003
- Article first published online: 3 APR 2003
- Manuscript Accepted: 19 DEC 2002
- Manuscript Received: 10 OCT 2002
Funded by
- Vlaams instituut voor de bevordering van het wetenschappelijk-technologisch onderzoek in de industrie. Grant Number: IWT/SB/11127
- Bijzonder Onderzoeksfonds Ghent University. Grant Number: BOF01/DCO/068
- Bijzonder Onderzoeksfonds Ghent University. Grant Number: BOF00/DOC/031
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab, Graefe's Archive for Clinical and Experimental Ophthalmology, 2012,
- 2, , Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases, Clinical and Developmental Immunology, 2012, 2012, 1
- 3, , , , , Chilblain lupus induced by TNF-α antagonists: a case report and literature review, Clinical Rheumatology, 2011,
- 4
- 5, , , , , Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases, Journal of Autoimmunity, 2011, 37, 4, 273
- 6
- 7, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , TNF alpha antagonist therapy and safety monitoring, Joint Bone Spine, 2011, 78, 15
- 8, , , Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells, Clinical Immunology, 2011, 140, 1, 8
- 9
- 10
- 11
- 12
- 13, , , , , Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study, British Journal of Dermatology, 2010, 162, 4Direct Link:
- 14
- 15, , , Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment, Rheumatology, 2010, 49, 5, 891
- You have free access to this content16, , , , , , , Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice, Alimentary Pharmacology & Therapeutics, 2010, 31, 5Direct Link:
- 17, , , , , Infliximab-related hepatitis: discussion of a case and review of the literature, Internal and Emergency Medicine, 2010, 5, 3, 193
- You have free access to this content18, , , Innate pathways to B-cell activation and tolerance, Annals of the New York Academy of Sciences, 2010, 1183, 1Direct Link:
- 19, , , , Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report, Joint Bone Spine, 2010, 77, 5, 484
- 20
- 21, , , , , , Anti-TNFalpha blockers, autoantibodies and autoimmune diseases, Joint Bone Spine, 2009, 76, 4, 333
- 22, , , , , , Antinuclear antibodies: A marker associated with steroid dependence in patients with ulcerative colitis, Inflammatory Bowel Diseases, 2009, 15, 7Direct Link:
- 23, , , , , , Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review, Journal of the American Academy of Dermatology, 2009, 61, 3, 486
- 24, , , Overlapping presentation of fungal tubulointerstitial nephritis in an immunosuppressed pediatric patient, Pediatric Nephrology, 2009, 24, 8, 1573
- 25, , Pegylated interferon alfa-2B induced lupus in a patient with chronic hepatitis B virus infection: case report, Clinical Rheumatology, 2009, 28, 10, 1241
- 26, , , , , , , , Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis, Joint Bone Spine, 2009, 76, 3, 248
- 27, , Autoantibody production in patients treated with anti-TNF-α, Expert Review of Clinical Immunology, 2008, 4, 2, 275
- 28, , Drug Insight: autoimmune effects of medications—what's new?, Nature Clinical Practice Rheumatology, 2008, 4, 3, 136
- 29, , , , , , , , , , , Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients, Journal of Clinical Immunology, 2008, 28, 5, 445
- 30, , , Lewis–Sumner syndrome associated with infliximab therapy in rheumatoid arthritis, Muscle & Nerve, 2008, 38, 4Direct Link:
- 31, , , , , , , , Lupus érythémateux cutané induit par étanercept au cours de la polyarthrite rhumatoïde, La Revue de Médecine Interne, 2008, 29, 9, 744
- 32, , , , , , , , , , TNFα blockade in human diseases: Mechanisms and future directions, Clinical Immunology, 2008, 126, 2, 121
- 33, Update on treatment in acute stage of Kawasaki disease, Korean Journal of Pediatrics, 2008, 51, 5, 457
- 34, , , , , , , , , A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity, British Journal of Dermatology, 2007, 156, 2Direct Link:
- 35, , , , , , Biological and clinical effects of anti-TNFα treatment, Autoimmunity Reviews, 2007, 7, 1, 35
- 36, , Functions of TNF and its Receptors in Renal Disease: Distinct Roles in Inflammatory Tissue Injury and Immune Regulation, Seminars in Nephrology, 2007, 27, 3, 286
- 37, , , , Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease, Drug Discovery Today, 2007, 12, 3-4, 125
- 38, , The use of TNF-α blocking agents in rheumatoid arthritis: an update, Expert Opinion on Pharmacotherapy, 2007, 8, 13, 2089
- 39, , , Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab, Actas Dermo-Sifiliográficas, 2007, 98, 10, 657
- 40
- 41, , Adalimumab for rheumatoid arthritis, Expert Opinion on Biological Therapy, 2006, 6, 12, 1349
- 42
- 43, , Anti-TNF-α agents in the treatment of psoriatic arthritis, Expert Opinion on Biological Therapy, 2006, 6, 2, 99
- 44, , , Biologic therapies for inflammatory eye disease, Clinical & Experimental Ophthalmology, 2006, 34, 4Direct Link:
- 45, , Les anti-TNF : une contre-indication ou un traitement prometteur du lupus ?, La Revue de Médecine Interne, 2006, 27, 2, 87
- 46, , Musculoskeletal manifestations and autoimmune diseases related to new biologic agents, Current Opinion in Internal Medicine, 2006, 5, 2, 183
- 47, , Toxicity of infliximab in the course of treatment of Crohn’s disease, Expert Opinion on Drug Safety, 2006, 5, 1, 9
- 48, Vascularites systémiques, syndromes auto-immuns et inhibiteurs du TNFalpha, La Revue de Médecine Interne, 2006, 27, 5, 363
- 492 Diseases: Management of patients presenting the first signs or a history of autoimmune disease?, Joint Bone Spine, 2005, 72, S3
- 50, , , , , , Aggravation d’un lupus érythémateux subaigu sous infliximab, Annales de Dermatologie et de Vénéréologie, 2005, 132, 4, 349
- 51, , , , Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases, Allergology International, 2005, 54, 2, 191
- 52, , , Anti-Tumor Necrosis Factor Therapy Is Tolerated in an Individual With Homozygous Complement C2 Deficiency, JCR: Journal of Clinical Rheumatology, 2005, 11, 3, 180
- 53, , , , , , , , Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment, Rheumatology International, 2005, 26, 1, 58
- 54, , , , , , Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate, Joint Bone Spine, 2005, 72, 1, 48
- 55, , , , , , , , Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study, Alimentary Pharmacology & Therapeutics, 2005, 22, 5Direct Link:
- 56, , , , , , Autoimmunity and Anti-TNF-α Agents, Annals of the New York Academy of Sciences, 2005, 1051, 1Direct Link:
- 57, , , , , , , C100 - Auto-immunité biologique et efficacité à long terme de l’infliximab (rémicade) dans le psoriasis sévère : série prospective de 31 patients, Annales de Dermatologie et de Vénéréologie, 2005, 132, 64
- 58, , , , , , , , Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry, PROTEOMICS, 2005, 5, 8Direct Link:
- 59, , Diverse effects of infliximab and etanercept on T lymphocytes, Seminars in Arthritis and Rheumatism, 2005, 34, 5, 23
- 60, , , , , Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies, Journal of Immunological Methods, 2005, 300, 1-2, 124
- 61, , Infliximab for the treatment of ankylosing spondylitis, Expert Opinion on Biological Therapy, 2005, 5, 8, 1095
- 62, , , , , , Infliximab, but not etanercept, induces IgM anti–double-stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis, Arthritis & Rheumatism, 2005, 52, 7Direct Link:
- 63, , , , , Management of hepatitis C virus-related arthritis, Expert Opinion on Pharmacotherapy, 2005, 6, 1, 27
- 64, , , , , , , Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor, Arthritis & Rheumatism, 2005, 52, 2Direct Link:
- 65, , Update on the British Society for Rheumatology guidelines for prescribing TNFÂ blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001), Rheumatology, 2005, 44, 2, 157
- 66, , , , , , , Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies, Journal of Internal Medicine, 2004, 255, 3Direct Link:
- 67, , , , , , , , , Anti-TNFα therapy in rheumatoid arthritis and autoimmunity, Rheumatology International, 2004, 26, 3, 209
- 68
- 69, , , , , Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide, Arthritis & Rheumatism, 2004, 50, 12Direct Link:
- 70, , , , , , , , , , , , , , Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS), Arthritis & Rheumatism, 2004, 50, 4Direct Link:
- 71
- 72, , , Sepsis as a Possible Adverse Drug Reaction in Patients With Rheumatoid Arthritis Treated With TNF?? Antagonists, JCR: Journal of Clinical Rheumatology, 2004, 10, 3, 119
- 73, , , , , , , Structure-Modifying Capacity of Anti-Tumour Necrosis Factor-?? Therapy in Ankylosing Spondylitis, Drugs, 2004, 64, 24, 2793
- 74, , The use of TNF-α blocking agents in rheumatoid arthritis: an overview, Expert Opinion on Pharmacotherapy, 2004, 5, 3, 581
- 75
- 76, , , , , , Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation, Rheumatic Disease Clinics of North America, 2003, 29, 3, 463
- 77, , , , , , , , Infliximab-induced lupus in Crohn’s disease: a case report, Digestive and Liver Disease, 2003, 35, 11, 814
- 78, , , , , , Biologics for chronic plaque psoriasis, The Cochrane Library,Direct Link:
- 79, , , , , , Biologics for chronic plaque psoriasis, The Cochrane Library,Direct Link:
- 80, , , , , , Ustekinumab for plaque psoriasis, The Cochrane Library,Direct Link: